Introduction To CAR T-Cell Therapy Part 2: Additional Considerations & Future Opportunities

By Ashley Herrick

Beginning in 2017 with the approvals of tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), chimeric antigen receptor (CAR) T-cell therapies have changed the treatment paradigm for patients with certain hematologic malignancies. Since those initial approvals, three other CAR T-cell therapies have been approved for various hematologic malignancies, but many challenges still limit the therapeutic efficacy of current CAR T-cell therapies and their use in solid tumors.

In our previous post, we covered the background and current development landscape for CAR T-cell therapies. In this post, we address the advantage and challenges of this approach, strategies for managing cytokine release syndrome (CRS), and the future of CAR T-cell therapy.